EPrints - Publications Repository

Copland, Mhairi and Ariti, Cono and Thomas, Ian F. and Upton, Laura and Sydenham, Mia and Mehta, Priyanka and Islam, Shahid and Kjeldsen, Lars and Burnett, Alan K. and Hills, Robert K. and Russell, Nigel and Dennis, Mike (2024) A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial. British Journal of Haematology, 204 (3). ISSN 0007-1048

AI Summary:

The study evaluated lenalidomide (LEN) in combination with low-dose cytosine arabinoside (LDAC) in patients aged 60 years or older who were unfit for intensive therapy. The results showed that the addition of LEN to LDAC was associated with a higher overall response rate, but did not improve overall survival.

AI Topics:

The following topics are generate through an AI service. Clicking on them will take you to a search result page with related items.

Abstract

Improving outcomes for older patients with acute myeloid leukaemia remains an unmet need. As part of the LI-1 trial, we evaluated lenalidomide (LEN), in combination with low-dose cytosine arabinoside (LDAC) in patients aged >60 years unfit for intensive therapy and compared this to LDAC alone. 202 patients randomised 1:1 were evaluable. Overall response rate (CR+CRi) was higher for LDAC+LEN versus LDAC (26% and 13.7%, respectively, P=0.031). However, there was no difference in overall survival between the arms (14% and 11.5% at 2 years for LDAC+LEN and LDAC, respectively). Addition of LEN was associated with increased toxicity and supportive care requirements.

People

Copland, Mhairi

Author

Publications

Copland, Mhairi (2024) Triplet therapy for advanced BCR::ABL1 positive myeloid leukaemias. Lancet Haematology, 11 (11). e807-e808. ISSN 2352-3026

Innes, Andrew I. and Hayden, Chloe and Orovbon, Victoria and Claudiani, Simone and Fernando, Fiona and Khan, Afzal and Rees, David and Byrne, Jennifer and Gallipoli, Paolo and Francis, Sebastian and Copland, Mhairi and Horne, Gillian and Raghavan, Manoj and Arnold, Claire and Collins, Angela and Cranfield, Tanya and Cunningham, Nicholas and Danga, Akila and Forsythe, Peter and Frewin, Rebecca and Garland, Paula and Hannah, Guy and Avenoso, Daniele and Hassan, Sandra and Huntly, Brian J.P. and Husain, Jissan and Makkuni, Sudhakaran and Rothwell, Kate and Khorashad, Jamshid and Apperley, Jane F. and Milojkovic, Dragana (2024) Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy. Leukemia, 38 (11). pp. 2443-2455. ISSN 0887-6924

Publications

See full publications list

Organisations

Copyright © 2023 The Authors

Copyright holder

Wiley

Publisher

Texts

348:359

348:359

309444.pdf - Published Version
Available under License Creative Commons Attribution.

Download (512kB) |

Information

Title:

A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial

Creators:

Identification Number:

10.1111/bjh.19220

Date:

March 2024

Divisions:

College of Medical Veterinary and Life Sciences > School of Cancer Sciences

Publisher:

Wiley

Additional Information:

Funding: We are grateful to the NIHR for supporting local trial delivery, Blood Cancer UK for research support, the Haematology Clinical Trials Unit and Centre for Trials Research, Cardiff University for managing the trial and Celgene for providing drug and additional support for this Investigator Initiated Trial.

Library

URI:

https://pub.demo35.eprints-hosting.org/id/eprint/348

Item Type:

Article

Depositing User:

Unnamed user with email ejo1f20@soton.ac.uk

Date Deposited:

11 Jun 2025 16:37

Revision:

Last Modified:

12 Jun 2025 10:10